INTRODUCTION AND OBJECTIVES:
The prevalance of azoospermia at the time of diagnosis for testicular cancer is between 6-24%. Onco-TESE is an option to preserve and treat fertility in these men at the time of their orchiectomy. Tumor size has been found to predict spermatogenesis on pathology after radical orchiectomy. However, no predictors of success have been documented for onco-TESE. We aim to understand potential predictors of its success in order to inform patients and healthcare professionals about future paternity.
METHODS: A retrospective analysis of onco-TESE procedures conducted between 2015-2018 at Guys Hospital, London, was undertaken (16 patients and 20 testes). Of the 20 tumours present there were 12 seminomas, 3 mixed germ cell tumours, 3 burned out lesions, one leydig cell tumour and 1 metastasis. 13/20 testis contained ITGCN. Onco-TESE was carried out only ipsilateral to the tumour.
RESULTS: Spermatogenesis was found in 13/20 testes (65%). The mean age at the time of surgery was 34 years (range 25-43 CONCLUSIONS: Onco-TESE is a successful treatment option for the infertile, azoospermic testicular cancer patient. We were unable to identify any predictors of success for Onco-TESE.
Source of Funding: none

PD34-11 DEFINING THE FEASIBILITY OF FERTILITY PRESERVATION IN PRE-PUBERTAL MALES SCHEDULED TO UNDERGO CHEMOTHERAPY
Helen Levey Bernie*, Elizabeth A Schofield, Nicole Benfante, John P Mulhall, NY, NY INTRODUCTION AND OBJECTIVES: Overall incidence rates of childhood cancer vary between 50-200/million children across the world. Childhood cancer survival rates are high, as are the late effects of gonadotoxic agents, such as infertility, in cancer survivors. While cryopreservation of sperm in adults is widely used, cryopreservation of testicular tissue in pre-pubertal boys has only recently been applied as a means to help preserve future fertility in pre-pubertal boys with cancer. The objective of this study is to present our experience of pre-pubertal pre-chemotherapy fertility preservation.
METHODS: All pre-pubertal pre-chemotherapy patients who underwent fertility preservation using testicular sperm extraction (TESE) were analyzed. Parents were informed that: the procedure was experimental, given that it is unknown if the tissue will be of use in the future; the procedure had to be performed under an anesthetic for another procedure (infusion port, bone marrow aspirates); the procedure would not be covered by insurance. A unilateral window technique was utilized as most patients were to undergo chemotherapy within 48 hours of TESE. Safety data including rates of infection, hematoma development or delay in chemotherapy initiation were recorded.
RESULTS: A total of 24 pre-pubertal males who had a mean age of 10AE5 years, (range 6 months -14 years), constituted the study population. The mean FSH level was 7.9AE7.3 (range 0.2-19.9) iU/ml.
Our cohort had a median Tanner stage of 1, with mean testicular volumes of 4.0 AE4.0. The most common childhood cancers in this cohort were sarcomas (46%), lymphomas (13%), and leukemias (13%). The procedure took an average of 22 AE11 minutes. The tissue was sent to the sperm bank where it was cryopreserved. Viability testing on the first 10 specimens revealed healthy testicular tissue. No wound infections or scrotal hematomas occurred postoperatively. All patients were able to commence chemotherapy on schedule, usually within 24 hours or less of the fertility procedure.
CONCLUSIONS: Fertility preservation in pre-pubertal prechemotherapy patients is a safe and feasible operation.
Source of Funding: none
PD34-12 "TESTOSTERONE BOOSTING" SUPPLEMENTS COMPOSITION AND CLAIMS ARE NOT SUPPORTED BY THE ACADEMIC LITERATURE
Hatim Thaker*, Chase Clemesha, Mary K. Samplaski, Los Angeles, CA INTRODUCTION AND OBJECTIVES: Many men take overthe-counter "testosterone (T) boosting" supplements in hopes of improving their T naturally. However, these claims may not be supported by evidence. We sought to evaluate the composition of "T boosting" supplements, their advertised claims, and compare this with the published literature.
METHODS: 50 "T booster" supplements were evaluated for active ingredients and product claims. PubMed was reviewed for each component for any literature supporting the claims. We then reviewed the Recommended Daily Allowance (RDA) and upper tolerable intake level for each component.
RESULTS: 90% of supplements claimed to "boost T", 50% "improve libido" and 48% to make men "feel stronger". Other claims included "building body mass" (62%), "increased energy" (30%) and "burn fat" (28%). 111 components were found, with a mean number of 7.1 per product (range 18, median 7, mode 6, standard deviation 4.32).
At PubMed search, 4 components had prospective data. Fenugreek and Shilajit: positive effect on T; D-Aspartic acid and Vitamin D: no effect on T. 4 components had non-prospective human data showing positive effect on T; 6 had animal data showing positive effect; 2 had non-prospective human data showing negative effect; 8 had animal data showing negative effect. 67 (60.4%) had no published data on their effect on T.
27 supplements contained Fenugreek and/or Shilajit. 42 had components with non-prospective human data showing a positive effect on T; 42 had animal data showing a positive effect; 6 had nonprospective human data showing a negative effect; 21 had animal data showing a negative effect. One supplement had no components with human or animal data supporting a positive effect on T.
For the 45 supplements that claimed to boost T, Table 1 lists the most common components, versus RDA. 2 supplements had over the upper tolerable intake of zinc.
CONCLUSIONS: 90% of "T booster" supplements claimed to boost T. However, only 12% of these had prospective human data to support these claims, based on their components. 48% contained components with data to suggest a negative effect on T. Many had supra-therapeutic doses of vitamins and minerals, occasionally over the upper tolerable limit, with associated risks. Patients need to know that "T booster" supplements may not contain components with mechanisms to support their claims.
